S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:SABS

SAB Biotherapeutics (SABS) Stock Forecast, Price & News

$0.95
+0.01 (+1.06%)
(As of 06/6/2023 ET)
Compare
Today's Range
$0.90
$0.95
50-Day Range
$0.38
$1.09
52-Week Range
$0.37
$1.93
Volume
100,380 shs
Average Volume
816,805 shs
Market Capitalization
$47.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.67

SAB Biotherapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
286.0% Upside
$3.67 Price Target
Short Interest
Healthy
1.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.53) to ($0.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

427th out of 981 stocks

Biological Products, Except Diagnostic Industry

63rd out of 156 stocks


SABS stock logo

About SAB Biotherapeutics (NASDAQ:SABS) Stock

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SABS Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
SAB Biotherapeutics Inc.
8-K: SAB Biotherapeutics, Inc.
Short Volatility Alert: Sab Biotherapeutics
See More Headlines

SABS Price History

SABS Company Calendar

Last Earnings
5/16/2023
Today
6/06/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SABS
Fax
N/A
Employees
139
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.67
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+286.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,740,000.00
Net Margins
-213.54%
Pretax Margin
-214.06%

Debt

Sales & Book Value

Annual Sales
$23.90 million
Book Value
$0.72 per share

Miscellaneous

Free Float
34,321,000
Market Cap
$47.88 million
Optionable
Not Optionable
Beta
1.41

Key Executives

  • Mr. Samuel J. Reich (Age 48)
    Exec. Chairman
    Comp: $212.58k
  • Dr. Eddie Joe Sullivan Ph.D. (Age 57)
    Co-Founder, Pres, CEO & Director
    Comp: $526.82k
  • Ms. Christine E. Hamilton M.B.A. (Age 67)
    Co-Founder & Independent Director
    Comp: $25k
  • Dr. Edward D. Hamilton D.V.M.
    Co-Founder & Board Observer
  • Mr. Russell P. Beyer C.M.A. (Age 68)
    M.B.A., Exec. VP & CFO
  • Dr. Christoph Bausch M.B.A. (Age 52)
    Ph.D., Exec. VP & COO
  • Dr. Carlos N. Carillo Ph.D.
    Sr. VP of Regulatory Affairs
  • Dr. Alexandra Kropotova M.B.A. (Age 51)
    M.D., Exec. VP & Chief Medical Officer













SABS Stock - Frequently Asked Questions

Should I buy or sell SAB Biotherapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SABS shares.
View SABS analyst ratings
or view top-rated stocks.

What is SAB Biotherapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month target prices for SAB Biotherapeutics' shares. Their SABS share price forecasts range from $3.00 to $4.00. On average, they expect the company's stock price to reach $3.67 in the next year. This suggests a possible upside of 286.0% from the stock's current price.
View analysts price targets for SABS
or view top-rated stocks among Wall Street analysts.

How have SABS shares performed in 2023?

SAB Biotherapeutics' stock was trading at $0.5899 on January 1st, 2023. Since then, SABS shares have increased by 61.0% and is now trading at $0.95.
View the best growth stocks for 2023 here
.

Are investors shorting SAB Biotherapeutics?

SAB Biotherapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 665,400 shares, an increase of 28.3% from the April 30th total of 518,600 shares. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is presently 0.5 days. Currently, 1.9% of the shares of the company are short sold.
View SAB Biotherapeutics' Short Interest
.

When is SAB Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our SABS earnings forecast
.

How were SAB Biotherapeutics' earnings last quarter?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its earnings results on Tuesday, May, 16th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.07. The business earned $0.58 million during the quarter, compared to the consensus estimate of $5.56 million. SAB Biotherapeutics had a negative trailing twelve-month return on equity of 87.92% and a negative net margin of 213.54%.

What is SAB Biotherapeutics' stock symbol?

SAB Biotherapeutics trades on the NASDAQ under the ticker symbol "SABS."

Who are SAB Biotherapeutics' major shareholders?

SAB Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include First Manhattan CO. LLC. (0.55%).
View institutional ownership trends
.

How do I buy shares of SAB Biotherapeutics?

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SAB Biotherapeutics' stock price today?

One share of SABS stock can currently be purchased for approximately $0.95.

How much money does SAB Biotherapeutics make?

SAB Biotherapeutics (NASDAQ:SABS) has a market capitalization of $47.88 million and generates $23.90 million in revenue each year.

How many employees does SAB Biotherapeutics have?

The company employs 139 workers across the globe.

How can I contact SAB Biotherapeutics?

SAB Biotherapeutics' mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The official website for the company is www.bigcypressaccorp.com. The company can be reached via phone at 605-679-6980 or via email at ir@bigcypressaccorp.com.

This page (NASDAQ:SABS) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -